Cipla Shares Face Brokerage Downgrades Amid Lanreotide Supply Halt

• Brokerages Morgan Stanley and Nuvama have cut Cipla's target price and downgraded ratings due to a temporary halt in Lanreotide manufacturing.
• Cipla paused Lanreotide production to improve a facility after USFDA found deficiencies; the drug is a top 3 US product.
• USFDA inspection at Pharmathen's Rodopi facility (exclusive Lanreotide supplier) found 9 observations in November 2025.
• Lanreotide supply is expected to resume in the first half of fiscal year 2027; Cipla holds a 22% market share in the US.
• Nomura maintains a 'Buy' rating, believing potential sales loss is largely factored in, with a target of ₹1770 per share.

Why It Matters: Cipla faces brokerage downgrades and target price cuts due to a temporary halt in key drug Lanreotide production.